APOBEC3s are a family of cytidine deaminases involved in innate cellular immunity against virus including hepatitis B virus (HBV). A germline deletion across APOBEC3A and APOBEC3B (A3B) genes results in complete removal of the A3B coding region and destroys A3B expression. To determine whether this deletion affects susceptibility to HBV infection and HBV-related hepatocellular carcinoma (HCC), A3B genotypes were analyzed in 1124 individuals with HCC, 510 individuals with persistent HBV infection and 826 healthy controls and the association was estimated by odds ratio (OR) and 95% confidence interval (CI) computed by logistic regression. We also examined the effects of A3B on HBV genome hypermutation and replication in HCC cells. We observed a significantly higher frequency of the A3B deletion allele in persistent HBV carriers (33.3%; P 5 0.0015) and HCC patients (37.9%; P 5 1.28 3 10 211 ) compared with that in controls (27.5%). An increased risk for persistent HBV infection (OR 5 1.35, 95% CI: 1.03 -1.77) and HCC development (OR 5 1.90, 95% CI: 1.58 -2.28) was associated with at least one A3B deletion allele (1/2 or 2/2 genotype) compared with the 1/1 genotype. Transfection of A3B in HepG2 cells caused a substantial reduction of HBV RNA levels and G A hypermutation in the HBV genome. Interestingly, a cytidine deaminase null mutant of A3B (E255A) also inhibited HBV RNA production although it was unable to edit HBV. These results suggest that the deletion of A3B attenuates HBV clearance, which in turn may result in persistent HBV infection and increased risk for developing HCC. Further studies are needed to verify our findings.
INTRODUCTION
It has been well known that infection with hepatitis B or C virus (HBV or HCV) is the major etiological factor for the development of hepatocellular carcinoma (HCC) (1) . Previous studies have shown that chronic HBV carriers conferred 5-to 15-fold increased risk of developing HCC compared with general population (2) . However, although the virus infection is a high-risk factor, only a small portion of individuals with HBV or HCV infection develops HCC, suggesting that the host factors may also play important roles in the development of HCC. In the past two decades, evidence has been accumulated to show that host genetic makeup is involved in pathogenesis of virus-related HCC (3 -6) . Copy number variations (CNVs) are common hereditary variations in human genome and some CNVs have been associated with cancers (7 -9) .
APOBEC3s (A3s) gene cluster is located on chromosome 22q13.1 -q13.2, which includes seven members, A3A, APOBEC3B (A3B), A3C, A3DE, A3F, A3G and A3H. They all have the cytidine deaminase activity and are able to convert cytosine to uracil (10) (11) (12) . Most APOBEC3 proteins act as innate antiviral molecules and mediate restriction of retroviruses, endogenous retro-element and DNA virus, with a different spectrum of antiviral activities (12) . APOBEC3A has been shown to be able to limit the retro-transposition of L1 and Alu elements and the replication of parvoviruses (13, 14) , 1262-1269 doi:10.1093/hmg/dds513 Advance Access published on December 4, 2012 whereas A3B, APOBEC3C, APOBEC3DE, APOBEC3F and APOBEC3G can directly inhibit various retroviruses such as human immunodeficiency virus (HIV) (15) (16) (17) . Recent studies have also documented that APOBEC3A, A3B, APOBEC3C, APOBEC3F, APOBEC3G and APOBEC3H are able to edit the HBV genome (18) (19) (20) (21) (22) . Many G-to-A hypermutations of HBV in serum and liver samples raise the possibility that A3s may inhibit HBV infection.
A 29.5 kb deletion between exon 5 in A3A and exon 8 in A3B has recently been identified. This deletion results in complete removal of the A3B coding region and the hybrid gene contains the coding region of A3A and the 3 ′ -untranslated region of A3B (23) . It has been suggested that the homozygous deletion of A3B significantly increase host susceptibility to HIV-1 acquisition and progression to AIDS (24) . We therefore hypothesized that this common deletion in A3B disrupt the gene expression, which in turn might affect the innate cellular immunity resulting in increased susceptibility to HBV infection and its related HCC. To test this hypothesis, we performed a large case -control association study. In addition, we also conducted functional analyses to elucidate the potentially relevant mechanism.
RESULTS

A3B deletion is associated with risks of persistent HBV infection and HCC
The select characteristics of study subjects are summarized in Table 1 . The distributions of sex and age in HCC patients and healthy controls were similar, whereas more females and younger subjects were presented in the HBV carrier group. The proportions of smokers and drinkers were not significantly different in the three groups. These indicate that the matching of cases and controls was adequate. The frequency of the A3B deletion allele in HCC patients (37.9%) was significantly higher than that in HBV carriers (33.3%, P ¼ 0.0120) and healthy controls (27.5%, P ¼ 1.28 × 10
211
). The frequency of the A3B deletion allele in HBV carriers was also significantly higher than that in controls (P ¼ 0.0015). The genotype distributions of A3B in all three groups were in good agreement with that expected under the Hardy -Weinberg equilibrium. In the control group, the distributions of A3B genotypes were 53.2% for two copies (+/+), 38.6% for one copy (+/2) and 8.2% for zero copy (2/2), which differed significantly from those in the HCC group (37.7% for +/+, 48.8% for +/2 and 13.5% for 2/2; P ¼ 3.08 × 10
) and the HBV carrier group (43.5% for +/+; 46.3% for +/2 and 10.2% for 2/2; P ¼ 0.0029 (Table 2) . Interestingly, the distributions of A3B genotypes were also significantly different between the HCC patient group and the HBV carrier group (P ¼ 0.038); HBV carriers with at least one deletion allele (+/2 or 2/2 genotype) had 1.50-fold increased risk (95% CI: 1.13-1.98) for developing HCC compared with those with the non-deletion allele.
Deletion of the A3B gene obliterates A3B expression
Because the 29.5 kb deletion between exon 5 in A3A and exon 8 in A3B completely removes the A3B coding region, we expected that this genomic deletion might obliterate the expression of A3B. To examine this hypothesis, we performed real-time quantitative PCR (RT-qPCR) analysis of A3B mRNA levels in a set of normal liver tissues (n ¼ 14). As expected, the results showed that the mRNA levels of A3B in the liver samples with the A3B +/+ genotype were significantly higher than those in the liver samples with the A3B +/2 genotype [0.00102 + 0.00182 (n ¼ 6) versus 0.00028 + 0.00008 (n ¼ 6); P ¼ 0.0041]. However, the mRNA levels for the liver samples with the A3B 2/2 genotype (n ¼ 2) were under the detection limit ( Fig. 1 ). These results confirmed that the deletion of this genomic region indeed obliterate A3B expression.
The effect of A3B on HBV replication
The results of association analysis showing A3B deletion was associated with susceptibility to persistent HBV infection and HCC prompt us to examine the effect of A3B on HBV replication. Because A3s are single-strand DNA cytidine deaminase that can restrict virus replication and HBV has single-strand phase in its life cycle (25), we reasoned that A3B deletion might impair native antiviral immunity, leading to liver cells more vulnerable for persistent HBV infection. To test this, we co-expressed A3B or its mutant E255A ( Fig. 2A ) and HBV1.3 in HepG2 cells and examined whether A3B has an effect on HBV genome replication by measuring HBV viral RNA levels in the presence or absence of A3B expression. RT -qPCR analysis showed that the level of HBV viral RNA was significantly lower in HepG2 cells transfected with A3B expression vector than in HepG2 cells transfected with empty pcDNA6 vector ( . These results indicated a strong inhibitory effect of A3B on HBV replication. To further determine whether this inhibitory effect of A3B is deaminase dependent, we also measured the HBV viral RNA levels in HepG2 cells transfected with A3B E255A mutant. We found that the mean HBV viral RNA level in HepG2 cells transfected with A3B E255A decreased to the similar extent as in cells transfected with wild-type A3B, which was also significantly different from that in HepG2 cells transfected with empty pcDNA6 vector (48.65 + 2.10, n ¼ 8; P ¼ 6.81 × 10 24 ) (Fig. 2B ).
The effect of A3B on HBV hypermutation
We next determined the ability of A3B to edit HBV DNA. We isolated core-associated HBV DNA from the HepG2 cells and amplified different regions of the HBV genome by 3D-PCR that specifically amplified hyper-edited DNA (Fig. 3) . Sequencing results of the 3D-PCR products showed that A3B was able to edit HBV. The mutation frequency of HBV induced by A3B was 1.5 mutations per 100 bases, with the most common mutations being C T followed by G A (Fig. 3 and Supplementary Material, Table S1 ). However, in contrast to inhibition of HBV genome replication, mutant A3B E255A had almost no activity to edit HBV, suggesting an essential role of the cytidine deaminase activity of A3B for virus editing.
DISCUSSION
In the present study, we showed that a 29.5 kb deletion between exon 5 in A3A and exon 8 in A3B resulting in complete removal of the A3B coding region was significantly associated with increased susceptibility to persistent HBV infection and the development of HBV-related HCC. This genomic DNA deletion destroys the production of A3B, an important deaminase that functions as innate immunity against virus infection, resulting in diminished HBV editing and increased HBV replication. To the best of our knowledge, this is the first report linking the CNV of A3B to human HCC.
There has been a substantial amount of data showing that both innate and adaptive immunity contribute to the control of HBV replication (26, 27) . Recent association studies have also provided evidence that genetic variations in immune gene loci increase risks of HBV infection and HCC (28) (29) (30) . APOBEC3 proteins are crucial immune molecules and they are often up-regulated in hepatocytes in Figure 1 . The effect of the A3B gene deletion on APOBEC3B mRNA expression in human liver tissues. The amount of RNA in different samples was normalized to GAPDH RNA. Columns, mean; bars, + SE. An expression level among the +/2 (n ¼ 6) genotype was significantly (P ¼ 0.0041) lower than that among the +/+ genotype (n ¼ 6). The RNA levels for the 2/2 genotype (n ¼ 2) were under the detection limit. response to interferon stimulation, which is an important defense mechanism for the clearance of foreign DNA including virus DNA (31) . Thus, genomic deletion of A3B would be expected to decrease cellular anti-virus activity and thus increases risks of virus-related diseases. For example, previous study has shown that although A3B has only weak anti-HIV activity, deletion of A3B is associated with an increased risk of HIV infection (24) . Editing of virus is the major function of APOBEC3 family. In the present studies, we did find that A3B is able to effectively edit the HBV genome. The HBV genome templates edited by A3B might produce non-function viral proteins or mutated virus that limits their infection ability. Furthermore, the clearance of HBV by APOBEC3 should not cause any damage to hepatocytes and chronic inflammation, a well-known mechanism in HBV-induced carcinogenesis of the liver (32) . Thus, deletion of the A3B gene might attenuate HBV clearance, which in turn results in persistent HBV infection and increased risk for the development of HCC.
In the present study, we also found that both wild-type A3B and A3B E255A, a mutant that is unable to edit HBV, had a strong inhibitory effect on HBV replication. These results suggest that A3B might have functions other than deamination to clear HBV. Recently, Turelli et al. (33) reported that APOBEC3G, another member of APOBEC3 family, is able to inhibit HBV replication in a deaminase-independent manner. This finding strongly supports our observation, because APOBEC3G and A3B are in a highly conserved family and might share the same function. Thus, this deaminase-independent function of A3B may also play important role in protection from HBV infection. In this context, it would be biologically plausible that the deletion of A3B may attenuate innate cellular immunity against HBV and thus confer the host persistence for HBV infection and susceptibility to sequential HCC. In addition, A3B also participates in the reaction of interferon, which is often used in clinic to treat persistent HBV infection and chronic hepatitis. However, it has been shown that interferon-induced up-regulation of A3B differs greatly in individuals (34) , which would be expected to be due to genetic polymorphisms of A3B such as the deletion. Therefore, deletion of A3B might not only affect innate cellular immunity against virus, but also affect response to interferon therapy, which in turn results in an unfavorable outcome of HBV infection.
Recently, Abe et al. (35) also reported a case -control study on this same structural variation of A3B and chronic HBV infection in a Japanese population. However, they found null association between A3B deletion and chronic HBV carrier state or HCC; rather, they found an association of A3B deletion with mild liver fibrosis. The reason for this discrepancy between their results and ours is currently unknown. Although the allelic and genotype frequencies of A3B deletion in the control subjects of both studies are quite similar, the relatively small sample size in their study (only 65 HCC and 469 controls) might have limited their statistical power. In addition, confounding of other factors in different populations, such as life-style factors, clinical conditions and other genetic variations influencing HBV infection and outcome, should also be considered. Nevertheless, while it is clear in the present study that the deletion of A3B was associated with the development of HCC, the association with the development of chronic HBV infection or the progression from chronic HBV infection to HCC tumorigenesis is only suggestive and needs to be further validated. In addition, we would knowledge that although our study subjects were all Han Chinese, population substructure cannot be ruled out formally. Given the wide variation in the allele frequency of this variant across populations, the possibility that our results are false positive might exist and further studies are needed to be certain of the association.
It should be noted that the DNA-editing function of A3B might have dual roles in anti-virus and cancer development (36) . A3B indeed edits the HBV genome and this may trigger degradation of HBV by nucleases. However, on the other hand, editing of the virus genome might otherwise create some mutated HBV that are of benefit for persistent infection and/or cause of HCC. Curiously, A3B is the only human DNA deaminase with an apparent steady-state nuclear localization (31, 37) . This localization might be required for protection against HBV cccDNA that is also located in nuclei and is essential for maintaining HBV copies in hepatocytes (25) . Although not elucidated, it has been supposed that A3s could be responsible for endogenous mutations (38) . A recent study analyzing somatic mutations in breast cancer revealed base substitutions preferable to cytosine at TpC dinucleotides, which is typical site targeted by A3s (39) . Although transfect experiments did not support that A3s induce endogenous mutations (40) , A3B is overexpressed in many types of tumor tissues (11, 36) . Therefore, the role of A3B deletion in other non-virus-related cancers should be investigated.
In conclusion, based on a large case -control analysis and functional assays, we have identified A3B deletion associated with susceptibility to persistent HBV infection and HCC development. These results might advance our understanding of genetic factors influencing HBV infection and outcome. If the results are validated in more studies, it might also have potential implication in prevention and clinical care of HBV infection and HCC.
MATERIALS AND METHODS
Study subjects
The association study included 1124 patients with HBVrelated HCC, 510 individuals with persistent HBV infection and 826 healthy controls. All subjects were ethnic Han Chinese. The HCC patients were recruited between 1998 and 2011 at Cancer Hospital, Chinese Academy of Medical Sciences (Beijing). The diagnosis of HCC was all confirmed by histopathology. We selected the samples for HBV positive but HCV negative according to serology tests and infection history. Eligible persistent HBV carriers were serum HBV surface antigen (HBsAg) positive for .6 months and the presence of HBeAg for .1 month or undetectable HBeAg and positive for hepatitis B e antibody (anti-HBe) with elevated HBV DNA levels but without cirrhosis symptom (41) . Healthy controls were cancer-free individuals selected from nutritional survey in Beijing, who were negative for HBsAg, HBeAg and anti-HBc. The selection criteria included no clinical, serological, history of evidence of liver disease and any other cancers and frequency matching to HCC patients on age and sex. Serum HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc and HCV antibody were measured by ELISA (Roche, Shanghai, China) according to the manufacturer's instruction. We also collected demographic data of each subject such as sex, age, smoking and drinking status. Individuals who smoked daily for at least 1 year were defined as smokers, and those who consumed alcohol drinks more than one time per week for over 6 months were considered drinkers. Written informed consent was obtained from all patients and this study was approved by the Institutional Review Board of the Chinese Academy of Medical Sciences Cancer Institute.
Genotype analysis
Genomic DNA was extracted from peripheral leukocytes and the A3B genotypes were identified using PCR as described previously (23) . RT -qPCR (ABI 7900HT, Applied Biosystems, Foster City, CA, USA) was conducted to further quantitatively confirm the genotyping results. The primers and probes based on the A3B deletion sequences and b-globin sequences, which has been proved to be two copies per diploid genome, were designed as described (23, 42) . Six serial 1:2 dilutions (20 -0.625 ng) of a standard DNA sample were used to generate standard curves of A3B and b-globin. Case and control samples were mixed and genotyped in each plate. The concordance between PCR-based and qPCR-based genotyping results is 99.3%. All primers and probes are shown in Supplementary Material, Table S2 .
Real-time analysis of A3B RNA in liver tissues
Fourteen non-tumor liver specimens were obtained from surgical resection. Total RNA was isolated from the liver samples using Trizol reagent (Life Technologies, Carlsbad, CA, USA). RNA (2 mg) was reverse transcribed into cDNA using oligo(dT) 18 (Takana, Japan) or random primers (New England Biolabs, Beverly, MA, USA) with or without M-MLV reverse transcriptase (Promega, Madison, WI, USA). mRNA levels were measured by RT -qPCR in triplicates with SYBR Premix Ex Taq (Takara). The measurement of the individual mRNA level was calculated relative to GAPDH using the 2 -DDCT method. All analyses were performed with the investigators being unaware of genotyping data.
Plasmid construction
A full-length of A3B cDNA was amplified from A3B expression plasmid (OriGene, Rockville, MD, USA) with the primers 5 ′ -atctaagcttgccaccatgaatccacagatcagaaatccg-3 ′ and 5 ′ -atccgct cgaggtttccctgattctggagaatggcccgcag-3 ′ , which contain Hind III or Xho I site, respectively. PCR product was cloned into pcDNA6/V5-HisA vector (Invitrogen, Carlsbad, CA, USA). This construct was then site-specifically mutated using the Muta-direct TM kit (SBS Genetech, Beijing, China) with the primers 5
′ -tacggccgccatgcggcgctgcgcttcttgga-3 ′ and 5 ′ -tccaag aagcgcagcgccgcatggcggccgta-3 ′ (underline indicates the mutation site) to create a A3B mutant, E255A, which contains 255Glu to 255Ala change. GAPDH expression vector was similarly constructed by PCR amplification of cDNA from normal liver tissue using the primers 5 ′ -aaattgagcccgcagcc-3 ′ and 5
′ -ggttgagcacagggtactttattg-3 ′ and insertion of PCR product into the pEASY-T1 Simple cloning vector (TransGen Biotech, Beijing, China). We also constructed the pcDNA-HBV plasmid that contains 1.3 HBV genome length (HBV genotype C, Genebank accession number: GU434374) allowing transcription of pre-genomic HBV RNA and high HBV replication to occur in cell lines.
Cell culture, transfection and western blotting
HepG2 cells was obtained from American Tissue Culture Collection (Manassas, VA, USA) and cultured in DMEM supplemented with 10% fetal bovine serum at 378C in 5% CO 2 . Cells were seeded onto 24-well culture plates at a cell density of 0.2 × 10 6 cells per well. After incubation for 24 h, cells were transfected with 0.2 mg A3B or E225A plasmid plus 0.3 mg HBV1.3, respectively, using Lipofectamine 2000 reagent (Life Technologies). Cells were harvested 48 h posttransfection and the whole cell lysates were separated on 12% SDS -PAGE and transferred to PVDF membrane. The membranes were blotted with V5 epitope antibody (Invitrogen) and horseradish peroxidase-conjugated secondary antibody for 1 h. Membranes were finally visualized by enhanced chemoluminescence reagents (Pierce, Rockford, IL, USA).
Isolation of core-associated HBV DNA
Cytoplasmic core-associated HBV DNA was isolated according to a published method (33) with modifications. Briefly, upon 48 h transfection, HepG2 cells were lysed with lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.1% SDS). After removing nuclei and insoluble materials by centrifugation, cell lysate was treated with DNase I (final concentration, 200 mg/ml) and RNase A (100 mg/ml) in 6 mM MgAC 2 for 1 h at 378C. The lysate was then briefly centrifuged and the supernatant was sedimented in 4% PEG 8000, 200 mM NaCl and 10 mM EDTA for 1 h on ice. The core particles were then pelleted by centrifugation and the pellets were digested by DNase I solution (40 mg/ml DNase I, 10 mM MgAC 2 ) for 1 h at 378C. Reactions were terminated by the addition of 10 mM EDTA, 1% SDS, 100 mM NaCl and 200 mg/ml of proteinase K and incubating at 558C for 1 h. HBV core-associated DNA was extracted with phenolchloroform.
Differential DNA denaturation PCR analysis of HBV hypermutation
Hypermutated HBV sequences were identified by using differential DNA denaturation PCR (3D-PCR). Two-round PCR were performed as previously described (43) . The thermal cycling conditions of the first PCR comprised an initial denaturing step at 958C for 5 min and 40 cycles of the standard three steps including 30 s at 958C, 30 s at 55-608C and 30 s at 728C. The second-round PCR was performed with the firstround product at 84-888C for 5 min and 40 cycles of the standard three steps including 30 s at 84-888C, 30 s at 55-608C and 30 s at 728C to specially amplify the A-T rich templates. The 3D-PCR products were gel-purified and ligated into the pEASY-T1 Simple cloning (TransGen Biotech). Clones were then picked and sequenced in an ABI 3730 sequencer (Applied Biosystems). We used the Mutation Explorer program (Todaysoft, Beijing, China) to identify mutations. The primers used for amplification of HBV DNA are shown in Supplementary Material, Table S2 .
Real-time analysis of HBV RNA in transfected cells
Total RNA was obtained from transfected cells and cDNA was prepared by the standard protocol as described above. The levels of HBV RNA were measured by real-time RT -qPCR with SYBR Premix Ex Taq (Takara). Each sample was measured three times and each assayed in triplicate and the intra-assay coefficient of variation was , 1%. HBV RNA values were normalized to GAPDH mRNA. The primers for detecting HBV RNA were 5 ′ -tcttcatcctgctgctatgcctcat-3 ′ / 5
′ -aaagccctacgaaccactgaacaaat-3 ′ and for detecting GAPDH RNA were 5 ′ -gaaggtgaaggtcggagtc-3 ′ /5 ′ -gaagatggtgatgggatttc-3
′ .
Statistical analysis
Two-side x 2 test was used to examine the differences in demographic variables and genotype frequencies among groups. The risk of persistent HBV infection or the development of HCC associated with A3B genotypes were estimated as ORs and 95% CIs computed using a multivariate logistic regression model including age, sex, smoking and drinking status as covariates. Student's t-test was used to examine the differences in gene expression levels. All analysis was carried out with the Statistical Analysis System software (Version 9.0; SAS Institute, Cary, NC, USA). P , 0.05 was considered statistically significant.
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